These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

120 related items for PubMed ID: 15850831

  • 1. Telomere length and telomerase activity in the BCR-ABL-transformed murine Pro-B cell line BaF3 is unaffected by treatment with imatinib.
    Hartmann U, Balabanov S, Ziegler P, Fellenberg J, van der Kuip H, Duyster J, Lipp HP, Bokemeyer C, Kanz L, Brümmendorf TH.
    Exp Hematol; 2005 May; 33(5):542-9. PubMed ID: 15850831
    [Abstract] [Full Text] [Related]

  • 2. Inhibition of human telomerase enhances the effect of the tyrosine kinase inhibitor, imatinib, in BCR-ABL-positive leukemia cells.
    Tauchi T, Nakajima A, Sashida G, Shimamoto T, Ohyashiki JH, Abe K, Yamamoto K, Ohyashiki K.
    Clin Cancer Res; 2002 Nov; 8(11):3341-7. PubMed ID: 12429620
    [Abstract] [Full Text] [Related]

  • 3. Rottlerin synergistically enhances imatinib-induced apoptosis of BCR/ABL-expressing cells through its mitochondrial uncoupling effect independent of protein kinase C-delta.
    Kurosu T, Tsuji K, Kida A, Koyama T, Yamamoto M, Miura O.
    Oncogene; 2007 May 10; 26(21):2975-87. PubMed ID: 17130834
    [Abstract] [Full Text] [Related]

  • 4. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.
    Barnes DJ, Palaiologou D, Panousopoulou E, Schultheis B, Yong AS, Wong A, Pattacini L, Goldman JM, Melo JV.
    Cancer Res; 2005 Oct 01; 65(19):8912-9. PubMed ID: 16204063
    [Abstract] [Full Text] [Related]

  • 5. Resistance to imatinib of bcr/abl p190 lymphoblastic leukemia cells.
    Mishra S, Zhang B, Cunnick JM, Heisterkamp N, Groffen J.
    Cancer Res; 2006 May 15; 66(10):5387-93. PubMed ID: 16707466
    [Abstract] [Full Text] [Related]

  • 6. BCR-ABL activity is critical for the immunogenicity of chronic myelogenous leukemia cells.
    Brauer KM, Werth D, von Schwarzenberg K, Bringmann A, Kanz L, Grünebach F, Brossart P.
    Cancer Res; 2007 Jun 01; 67(11):5489-97. PubMed ID: 17545631
    [Abstract] [Full Text] [Related]

  • 7. Imatinib mesylate (STI571) abrogates the resistance to doxorubicin in human K562 chronic myeloid leukemia cells by inhibition of BCR/ABL kinase-mediated DNA repair.
    Majsterek I, Sliwinski T, Poplawski T, Pytel D, Kowalski M, Slupianek A, Skorski T, Blasiak J.
    Mutat Res; 2006 Jan 31; 603(1):74-82. PubMed ID: 16388976
    [Abstract] [Full Text] [Related]

  • 8. Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.
    Koch A, Scherr M, Breyer B, Mancini A, Kardinal C, Battmer K, Eder M, Tamura T.
    Oncogene; 2008 Aug 07; 27(34):4678-89. PubMed ID: 18427551
    [Abstract] [Full Text] [Related]

  • 9. Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate.
    Nguyen TK, Rahmani M, Gao N, Kramer L, Corbin AS, Druker BJ, Dent P, Grant S.
    Clin Cancer Res; 2006 Apr 01; 12(7 Pt 1):2239-47. PubMed ID: 16609040
    [Abstract] [Full Text] [Related]

  • 10. Important therapeutic targets in chronic myelogenous leukemia.
    Kantarjian HM, Giles F, Quintás-Cardama A, Cortes J.
    Clin Cancer Res; 2007 Feb 15; 13(4):1089-97. PubMed ID: 17317816
    [Abstract] [Full Text] [Related]

  • 11. Telomeres and telomerase in chronic myeloid leukaemia: impact for pathogenesis, disease progression and targeted therapy.
    Keller G, Brassat U, Braig M, Heim D, Wege H, Brümmendorf TH.
    Hematol Oncol; 2009 Sep 15; 27(3):123-9. PubMed ID: 19569255
    [Abstract] [Full Text] [Related]

  • 12. N-acetyl cysteine enhances imatinib-induced apoptosis of Bcr-Abl+ cells by endothelial nitric oxide synthase-mediated production of nitric oxide.
    Rakshit S, Bagchi J, Mandal L, Paul K, Ganguly D, Bhattacharjee S, Ghosh M, Biswas N, Chaudhuri U, Bandyopadhyay S.
    Apoptosis; 2009 Mar 15; 14(3):298-308. PubMed ID: 19153832
    [Abstract] [Full Text] [Related]

  • 13. Imatinib mesylate minimally affects bcr-abl+ and normal monocyte-derived dendritic cells but strongly inhibits T cell expansion despite reciprocal dendritic cell-T cell activation.
    Boissel N, Rousselot P, Raffoux E, Cayuela JM, Soulier J, Mooney N, Charron D, Dombret H, Toubert A, Rea D.
    J Leukoc Biol; 2006 Apr 15; 79(4):747-56. PubMed ID: 16461746
    [Abstract] [Full Text] [Related]

  • 14. Role of p21(WAF1/CIP1) as an attenuator of both proliferative and drug-induced apoptotic signals in BCR-ABL-transformed hematopoietic cells.
    Forster K, Obermeier A, Mitina O, Simon N, Warmuth M, Krause G, Hallek M.
    Ann Hematol; 2008 Mar 15; 87(3):183-93. PubMed ID: 17960378
    [Abstract] [Full Text] [Related]

  • 15. Roots of imatinib resistance: a question of self-renewal?
    Burchert A.
    Drug Resist Updat; 2007 Mar 15; 10(4-5):152-61. PubMed ID: 17683977
    [Abstract] [Full Text] [Related]

  • 16. Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.
    Kurosu T, Ohki M, Wu N, Kagechika H, Miura O.
    Cancer Res; 2009 May 01; 69(9):3927-36. PubMed ID: 19366808
    [Abstract] [Full Text] [Related]

  • 17. STI-571 (imatinib mesylate) enhances the apoptotic efficacy of pyrrolo-1,5-benzoxazepine-6, a novel microtubule-targeting agent, in both STI-571-sensitive and -resistant Bcr-Abl-positive human chronic myeloid leukemia cells.
    Greene LM, Kelly L, Onnis V, Campiani G, Lawler M, Williams DC, Zisterer DM.
    J Pharmacol Exp Ther; 2007 Apr 01; 321(1):288-97. PubMed ID: 17202400
    [Abstract] [Full Text] [Related]

  • 18. Retroviral insertional mutagenesis identifies RUNX genes involved in chronic myeloid leukemia disease persistence under imatinib treatment.
    Miething C, Grundler R, Mugler C, Brero S, Hoepfl J, Geigl J, Speicher MR, Ottmann O, Peschel C, Duyster J.
    Proc Natl Acad Sci U S A; 2007 Mar 13; 104(11):4594-9. PubMed ID: 17360569
    [Abstract] [Full Text] [Related]

  • 19. Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML).
    Walz C, Sattler M.
    Crit Rev Oncol Hematol; 2006 Feb 13; 57(2):145-64. PubMed ID: 16213151
    [Abstract] [Full Text] [Related]

  • 20. [Monitoring bcr/abl mRNA levels in imatinib mesylate treated chronic myeloid leukemia patients by real-time quantitative RT-PCR].
    Qin YZ, Ruan GR, Liu YR, Li JL, Fu JY, Wang H, Chang Y, Jiang B, Jiang Q, Jiang H, Qiu JY, Chen SS, Lu DP.
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jan 13; 26(1):1-5. PubMed ID: 15946498
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.